NCT07071506View on ClinicalTrials.gov

New Methods for Evaluating Preventive Migraine Treatment

NARecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

March 4, 2025

Primary Completion Date

September 30, 2028

Study Completion Date

September 30, 2028

Conditions
MigraineMigraine With or Without AuraHeadache DisordersChronic Migraine, Headache
Interventions
DRUG

Active drug for chronic migraine treatment.

Standard dose of Fremanezumab, 225 mg (Ajovy) injected subcutaneously

DRUG

Placebo Subcutaneous injection

Inactive placebo (saline) injected subcutaneously in the same volume as the active drug

Trial Locations (2)

8000

RECRUITING

Department of Psychology and Behavioral sciences, Aarhus BSS, Aarhus University, Aarhus C

8200

RECRUITING

Department of Clinical Medicine, Aarhus University Hospital, Aarhus N

All Listed Sponsors
lead

University of Aarhus

OTHER